论文部分内容阅读
目的:探究围绝经期妇女使用米非司酮治疗功能失调性子宫出血的效果。方法:选取2015年3月—2015年7月之间就诊于我院的功能失调性子宫出血患者82例,所选患者年龄平均为(51.3±4.7)周岁,将所有患者随机分为两组,实验组40人,平均(47.5±5.4)周岁,在行诊断性刮宫术后第5d起使用米非司酮进行治疗;对照组42人,平均(49.1±5.1)周岁,同样在行诊断性刮宫术后第5d起使用安宫黄体酮进行治疗。嘱咐两组患者记录月经情况以及服药期间的不良反应情况,并在治疗30d后到院复查体内激素水平,包括卵泡生成素(FSH)、黄体生成素(LH)、雌二醇(E2)以及孕激素(P),并在超声下检查子宫内膜厚度。将两组患者情况进行对比。结果:所有患者治疗前后相比子宫内膜厚度情况以及血浆相关激素水平均有所降低,但是实验组效果更明显,两组相比差异有统计学意义(p<0.05)。在安全性方面,实验组在治疗过程中有3人发生不良反应,均为轻微恶心、呕吐的胃肠道症状,不良反应发生率为7.5%;对照组在治疗过程中有11人发生不良反应,有5人曾有恶心的症状出现,4人出现眩晕的症状,2人出现乏力的症状,的不良反应发生率为20.20%。两组不良反应发生情况相比差异明显(p<0.05)。结论:围绝经期妇女使用米非司酮治疗功能失调性子宫出血效果明显且不良反应发生率低,适合在临床上推广。
Objective: To investigate the effect of mifepristone on dysfunctional uterine bleeding in perimenopausal women. Methods: Totally 82 dysfunctional uterine bleeding patients were selected in our hospital from March 2015 to July 2015. The average age of selected patients was (51.3 ± 4.7) years old. All the patients were randomly divided into two groups, In the experimental group, 40 patients (average 47.5 ± 5.4) were treated with mifepristone on the 5th day after the diagnosis of curettage. In the control group, 42 patients (49.1 ± 5.1) On the 5th postoperative day, medroxyprogesterone was used for treatment. The two groups of patients were asked to record the menstrual situation and adverse reactions during the medication. The patients were admitted to the hospital for examination of the hormone levels after 30 days, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) Hormone (P), and examined for endometrial thickness under ultrasound. The two groups of patients were compared. Results: All patients had lower endometrial thickness and plasma hormone levels before and after treatment, but the effect of the experimental group was more obvious. The difference between the two groups was statistically significant (p <0.05). In terms of safety, the experimental group in the course of treatment there were 3 adverse reactions were mild nausea and vomiting gastrointestinal symptoms, the incidence of adverse reactions was 7.5%; control group in the course of treatment, 11 were adverse reactions , 5 people had symptoms of nausea, 4 symptoms of dizziness, 2 symptoms of fatigue, the incidence of adverse reactions was 20.20%. Adverse reactions between the two groups were significantly different (p <0.05). Conclusion: Peri-menopausal women use mifepristone to treat dysfunctional uterine bleeding with obvious effect and low incidence of adverse reactions, which is suitable for clinical promotion.